Acadia Investors Get Class Cert. In Suit Over Parkinson’s Drug
A California federal judge on Monday certified a class of Acadia Pharmaceuticals investors in a lawsuit accusing the company of making false and misleading statements regarding the likelihood that its Parkinson’s psychosis drug would also be approved for the broader use of dementia-related psychosis.
March 12, 2024